Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design

Current Topics in Medicinal Chemistry

Volumn 11, Issue 24, 2011, Pages 2959-2984

  Cai, Lifeng ^a   Gochin, Miriam ^b,c   Liu, Keliang ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b Touro University California   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fusion inhibitor; gp41; HIV 1; Membrane fusion; Peptide

Indexed keywords

CHOLESTEROL; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LIPOSOME; MEMBRANE FUSION PROTEIN; SIFUVIRTIDE; TIFUVIRTIDE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; INFRARED RADIATION; INFRARED SPECTROSCOPY; LIPID MEMBRANE; LIPID RAFT; MEMBRANE FLUIDITY; MEMBRANE FUSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; VIRUS CELL INTERACTION;

BIOCHEMISTRY; BIOPHYSICS; CELL MEMBRANE; DRUG DESIGN; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; VIRUS INTERNALIZATION;

EID: 84855252915     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798808497     Document Type: Article

References (157)

1. McEnery, R. Update on pandemic shows new HIV infections steadily declining. IAVI Rep., 2009, 13, 17.
2. Dorrucci, M. Epidemiology of HIV update. Recent. Prog. Med.,2010, 101, 12-15.
3. Steffen, I.; Pohlmann, S. Peptide-based inhibitors of the HIV enve-lope protein and other class I viral fusion proteins. Curr. Pharm. Des., 2010, 16, 1143-1158.
4. Granich, R.; Crowley, S.; Vitoria, M.; Smyth, C.; Kahn, J. G.; Bennett, R.; Lo, Y.-R.; Souteyrand, Y.; Williams, B. Highly active antiretroviral treatment as prevention of HIV transmission: Review of scientific evidence and update. Curr. Opin. HIV AIDS, 2010, 5, 298-304.
5. Yarchoan, R.; Broder, S. Development of antiretroviral therapy for the acquired-immunodeficiency-syndrome and related disorders - a progress report. New Eng. J. Med., 1987, 316, 557-564.
6. Furman, P. A.; Fyfe, J. A.; Stclair, M. H.; Weinhold, K.; Rideout, J. L.; Freeman, G. A.; Lehrman, S. N.; Bolognesi, D. P.; Broder, S.; Mitsuya, H.; Barry, D. W. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human-immunodeficiency-virus reverse-transcriptase. Proc. Natl. Acad. Sci. USA, 1986, 83, 8333-8337.
7. Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C. K.; Eckner, K.; Hattox, S.; Adams, J.; Rosehthal, A. S.; Faanes, R.; Eckner, R. J.; Koup, R. A.; Sullivan, J. L. Inhibition of HIV-1 replication by a nonnucleoside re-verse-transcriptase inhibitor. Science, 1990, 250, 1411-1413.
8. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I. W.; Vastag, K.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. L-735,524 -an orally bioavailable human-immunodeficiency-virus type-1 protease inhibitor. Proc. Natl. Acad. Sci. USA, 1994, 91, 4096-4100.
9. Deeks, S. G.; Smith, M.; Holodniy, M.; Kahn, J. O. HIV-1 protease inhibitors - a review for clinicians. JAMA-J. Am. Med. Assoc., 1997, 277, 145-153.
10. Walmsley, S.; Henry, K.; Katlama, C.; Nelson, M.; Castagna, A.; Reynes, J.; Clotet, B.; Hui, J.; Salgo, M.; DeMasi, R.; Delehanty, J. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J. Infect. Diseases, 2003, 188, 1827-1833.
11. [II] Hardy, N.; Skolnik, P. R. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharma-cotherapy, 2004, 24, 198-211.
12. Baldanti, F.; Paolucci, S.; Gulminetti, R.; Brandolini, M.; Bar-barini, G.; Maserati, R. Early emergence of raltegravir resistance mutations in patients receiving haart salvage regimens. J. Med. Virol., 2010, 82, 116-122.
13. Autran, B.; Carcelain, G.; Li, T. S.; Blanc, C.; Mathez, D.; Tubi-ana, R.; Katlama, C.; Debre, P.; Leibowitch, J. Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease. Science, 1997, 277, 112-116.
14. Finzi, D.; Hermankova, M.; Pierson, T.; Carruth, L. M.; Buck, C.; Chaisson, R. E.; Quinn, T. C.; Chadwick, K.; Margolick, J.; Brookmeyer, R.; Gallant, J.; Markowitz, M.; Ho, D. D.; Richman, D. D.; Siliciano, R. F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1997, 278, 1295-1300.
15. Williams, A. B. New horizons: Antiretroviral therapy in 1997. J. Assoc. Nurses. AIDS Care, 1997, 8, 26-38.
16. Yeni, P. Update on HAART in HIV. J. Hepatol., 2006, 44, S100-S103.
17. Johnson, V. A.; Brun-Vezinet, F.; Clotet, B.; Gunthard, H. F.; Kuritzkes, D. R.; Pillay, D.; Schapiro, J. M.; Richman, D. D. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med., 2009, 17, 138-45.
18. Aghokeng, A. F.; Ayouba, A.; Mpoudi-Ngole, E.; Loul, S.; Liegeois, F.; Delaporte, E.; Peeters, M. Extensive survey on the prevalence and genetic diversity of sivs in primate bushmeat provides insights into risks for potential new cross-species transmissions. Inf. Gen. Evol., 2010, 10, 386-396.
19. Eckert, D. M.; Kim, P. S. Mechanisms of viral membrane fusion and its inhibition. Ann. Rev. Biochem., 2001, 70, 777-810.
20. Harrison, S. C. Viral membrane fusion. Nat. Struct. Mol. Biol., 2008, 15, 690-698.
21. Colman, P. M.; Lawrence, M. C. The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol., 2003, 4, 309-319.
22. Eckert, D. M.; Malashkevich, V. N.; Hong, L. H.; Carr, P. A.; Kim, P. S. Inhibiting HIV-1 entry: Discovery of d-peptide inhibitors that target the gp41 coiled-coil pocket. Cell, 1999, 99, 103-115.
23. Liu, S. W.; Wu, S.; G. Jiang, S. B. HIV entry inhibitors targeting gp41: From polypeptides to small-molecule compounds. Curr. Pharm. Des., 2007, 13, 143-162.
24. Wild, C.; Oas, T.; McDanal, C.; Bolognesi, D.; Matthews, T. A synthetic peptide inhibitor of human-immunodeficiency-virus replication - correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA, 1992, 89, 10537-10541.
25. Jiang, S. B.; Lin, K.; Strick, N.; Neurath, A. R. HIV-1 inhibition by a peptide. Nature, 1993, 365, 113-113.
26. Jiang, S. B.; Lin, K.; Strick, N.; Neurath, A. R. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein-gp41. Biochem. Biophys. Res. Comm., 1993, 195, 533-538.
27. Wild, C.; Dubay, J. W.; Greenwell, T.; Baird, T.; Oas, T. G.; McDanal, C.; Hunter, E.; Matthews, T. Propensity for a leucine zipper-like domain of human-immunodeficiency-virus type-1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA, 1994, 91, 12676-12680.
28. Wild, C.; Greenwell, T.; Matthews, T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses, 1993, 9, 1051-1053.
29. Chan, D. C.; Fass, D.; Berger, J.; M.Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell, 1997, 89, 263-273.
30. Weissenhorn, W.; Dessen, A.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. Atomic structure of the ectodomain from HIV-1 gp41. Nature, 1997, 387, 426-430.
31. Tan, K. M.; Liu, J. H.; Wang, J. H.; Shen, S.; Lu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA, 1997, 94, 12303-12308.
32. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA, 1998, 95, 15613-15617.
33. Kilby, J. M.; Hopkins, S.; Venetta, T. M.; DiMassimo, B.; Cloud, G. A.; Lee, J. Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bo-lognesi, D.; Mathews, T.; Johnson, M. R.; Nowak, M. A.; Shaw, G.M; Saag, M. S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med., 1998, 4, 1302-1307.
34. Lazzarin, A.; Clotet, B.; Cooper, D.; Reynes, J.; Arasteh, K.; Nelson, M.; Katlama, C.; Stellbrink, H.; Delfraissy, J.; Lange, J.; Hu-son, L.; DeMasi, R.; Wat, C.; Delehanty, J.; Drobnes, C.; Salgo, M.; Grp, T. S. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New Eng. J. Med., 2003, 348, 2186-2195.
35. Zhou, G. Y.; Wu, D.; Hermel, E.; Balogh, E.; Gochin, M. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting gp41. Bioorg. Med. Chem. Lett., 2010, 20, 1500-1503.
36. Xie, D.; Yao, C.; Wang, L.; Min, W. J.; Xu, J. H.; Xiao, J. H.; Huang, M. X.; Chen, B.; Liu, B.; Li, X. L.; Jiang, H. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob. Agents Chemother., 2010, 54, 191-196.
37. Welch, B. D.; Francis, J. N.; Redman, J. S.; Paul, S.; Weinstock, M. T.; Reeves, J. D.; Lie, Y. S.; Whitby, F. G.; Eckert, D. M.; Hill, C. P.; Root, M. J.; Kay, M. S. Design of a potent d-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol., 2010, 84, 11235-11244.
38. Wang, Y.; Lu, H.; Zhu, Q.; Jiang, S.B.; Liao, Y. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. Bioorg. Med. Chem. Lett., 2010, 20, 189-192.
39. Chen, X.; Lu, L.; Qi, Z.; Lu, H.; Wang, J.; Yu, X. X.; Chen, Y. H.; Jiang, S. B. Novel recombinant engineered gp41 n-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or mi-crobicides. J. Biol. Chem., 2010, 285, 25506-25515.
40. Cai, L.; Jiang, S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem, 2010, 5, 1813-24.
41. Bianchi, E.; Anonymous; Pessi, A.; Geleziunas, R.; Bramhill, D. Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity. US 07811577, 2010.
42. Jiang, S. B.; Zhao, Q.; Debnath, A. K. Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des., 2002, 8, 563-580.
43. Jiang, S. B.; Lu, H.; Liu, S. W.; Zhao, Q.; He, Y. X.; Debnath, A. K. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother., 2004, 48, 4349-4359.
44. Bianchi, E.; Finotto, M.; Ingallinella, P.; Hrin, R.; Carella, A. V.; Hou, X. S.; Schleif, W. A.; Miller, M. D.; Geleziunas, R.; Pessi, A. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. USA, 2005, 102, 12903-12908.
45. Lalezari, J. P.; Bellos, N. C.; Sathasivam, K.; Richmond, G. J.; Cohen, C. J.; Myers, R. A.; Henry, D. H.; Raskino, C.; Melby, T.; Murchison, H.; Zhang, Y.; Spence, R.; Greenberg, M. L.; DeMasi, R. A.; Miralles, G. D.; Grp, T. S. T-1249 retains potent antiretrovi-ral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J. Infect. Dis., 2005, 191, 1155-1163.
46. Frey, G.; Rits-Volloch, S.; Zhang, X. Q.; Schooley, R. T.; Chen, B.; Harrison, S. C. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc. Natl. Acad. Sci. USA, 2006, 103, 13938-13943.
47. Cai, L. F.; Gochin, M. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1. An-timicrob. Agents Chemother., 2007, 51, 2388-2395.
48. Dwyer, J. J.; Wilson, K. L.; Davison, D. K.; Freel, S. A.; Seedorff, J. E.; Wring, S. A.; Tvermoes, N. A.; Matthews, T. J.; Greenberg, M. L.; Delmedico, M. K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. USA, 2007, 104, 12772-12777.
49. He, Y. X.; Cheng, J. W.; Lu, H.; Li, J. J.; Hu, J.; Qi, Z.; Liu, Z. H.; Jiang, S. B.; Dai, Q. Y. Potent HIV fusion inhibitors against enfu-virtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. USA, 2008, 105, 16332-16337.
50. He, Y. X.; Xiao, Y. H.; Song, H. F.; Liang, Q.; Ju, D.; Chen, X.; Lu, H.; Jing, W. G.; Jiang, S. B.; Zhang, L. Q. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem., 2008, 283, 11126-11134.
51. Oishi, S.; Ito, S.; Nishikawa, H.; Watanabe, K.; Tanaka, M.; Ohno, H.; Izumi, K.; Sakagami, Y.; Kodama, E.; Matsuoka, M.; Fujii, N. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. J. Med. Chem., 2008, 51, 388-391.
52. Qi, Z.; Shi, W. G.; Xue, N.; Pan, C. G.; Jing, W. G.; Liu, K. L.; Jiang, S. B. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J. Biol. Chem., 2008, 283, 30376-30384.
53. Stoddart, C. A.; Nault, G.; Galkina, S. A.; Thibaudeau, K.; Bakis, P.; Bousquet-Gagnon, N.; Robitaille, M.; Bellomo, M.; Paradis, V.; Liscourt, P.; Lobach, A.; Rivard, M. E.; Ptak, R. G.; Mankowski, M. K.; Bridon, D.; Quraishi, O. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor equipotent to C34 and T-20 in vitro with sustained activity in SCID-Hu Thy/Liv mice. J. Biol. Chem., 2008, 283, 34045-34052.
54. Cai, L. F.; Balogh, E.; Gochin, M. Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors. Antimicrob. Agents Chemother., 2009, 53, 2444-2449.
55. Ingallinella, P.; Bianchi, E.; Ladwa, N. A.; Wang, Y. J.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T. J.; Moore, J. P.; Miller, M. D.; Pessi, A. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. USA, 2009, 106, 5801-5806.
56. Katritzky, A. R.; Tala, S. R.; Lu, H.; Vakulenko, A. V.; Chen, Q. Y.; Sivapackiam, J.; Pandya, K.; Jiang, S. B.; Debnath, A. K. De sign, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors. J. Med. Chem., 2009, 52, 7631-7639.
57. Naito, T.; Izumi, K.; Kodama, E.; Sakagami, Y.; Kajiwara, K.; Nishikawa, H.; Watanabe, K.; Sarafianos, S. G.; Oishi, S.; Fujii, N.; Matsuoka, M. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob. Agents Chemother., 2009, 53, 1013-1018.
58. Wang, R. R.; Yang, L. M.; Wang, Y. H.; Pang, W.; Tam, S. C.; Tien, P.; Zheng, Y. T. Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem. Biophys. Res. Comm., 2009, 382, 540-544.
59. Munch, J.; Standker, L.; Adermann, K.; Schuz, A.; Schindler, M.; Chinnadurai, R.; Pohlmann, S.; Chaipan, C.; Biet, T.; Peters, T.; Meyer, B.; Wilhelm, D.; Lu, H.; Jing, W. G.; Jiang, S. B.; Forss-mann, W. G.; Kirchhoff, F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell, 2007, 129, 263-275.
60. Liu, J.; Deng, Y. Q.; Li, Q. N.; Dey, A. K.; Moore, J. P.; Lu, M. Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion. J. Virol., 2010, 84, 201-209.
61. Murray, E. J.; Leaman, D. P.; Pawa, N.; Perkins, H.; Pickford, C.; Perros, M.; Zwick, M. B.; Butler, S. L. A low-molecular-weight entry inhibitor of both CCR5-and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41. J. Virol., 2010, 84, 7288-7299.
62. Wexler-Cohen, Y.; Ashkenazi, A.; Viard, M.; Blumenthal, R.; Shai, Y. Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. Faseb J., 2010, 24, 4196-4202.
63. Wexler-Cohen, Y.; Shai, Y. Demonstrating the c-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. Faseb J., 2007, 21, 3677-3684.
64. [64] Wexler-Cohen, Y.; Shai, Y. Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. Plos Pathog., 2009, 5(7),e1000509.
65. Liu, S. W.; Jing, W. G.; Cheung, B.; Lu, H.; Sun, J.; Yan, X. X.; Niu, J. K.; Farmar, J.; Wu, S. G.; Jiang, S. B. HIV gp41 C-terminal heptad repeat contains multifunctional domains - relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem., 2007, 282, 9612-9620.
66. Peisajovich, S. G.; Gallo, S. A.; Blumenthal, R.; Shai, Y. C-terminal octylation rescues an inactive T20 mutant - implications for the mechanism of HIV/simian immunodeficiency virus-induced membrane fusion. J. Biol. Chem., 2003, 278, 21012-21017.
67. Chang, D. K.; Cheng, S. F.; Chien, W. J. The amino-terminal fusion domain peptide of human immunodeficiency virus type 1 gp41 inserts into the sodium dodecyl sulfate micelle primarily as helix with a conserved glycine at the micelle-water interface. J. Virol., 1997, 71, 6593-6602.
68. Suarez, T.; Gallaher, W. R.; Agirre, A.; Goni, F. M.; Nieva, J. L. Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycopro-tein: Putative role during viral fusion. J. Virol., 2000, 74, 8038-8047.
69. Lev, N.; Shai, Y. Fatty acids can substitute the HIV fusion peptide in lipid merging and fusion: An analogy between viral and palmi-toylated eukaryotic fusion proteins. J. Mol. Biol., 2007, 374, 220-230.
70. Pritsker, M.; Jones, P.; Blumenthal, R.; Shai, Y. C. A synthetic all d-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion. Proc. Natl. Acad. Sci. USA, 1998, 95, 7287-7292.
71. Kliger, Y.; Peisajovich, S. G.; Blumenthal, R.; Shai, Y. Membrane-induced conformational change during the activation of HIV-1 gp41. J. Mol. Biol., 2000, 301, 905-914.
72. Buzon, V.; Cladera, J. Effect of cholesterol on the interaction of the HIV gp41 fusion peptide with model membranes. Importance of the membrane dipole potential. Biochemistry, 2006, 45, 15768-15775.
73. Buzon, V.; Padros, E.; Cladera, J. Interaction of fusion peptides from HIV gp41 with membranes: A time-resolved membrane binding, lipid mixing, and structural study. Biochemistry, 2005, 44, 13354-13364.
74. Moreno, M. R.; Guillen, J.; Perez-Berna, A. J.; Amoros, D.; Gomez, A. I.; Bernabeu, A.; Villalain, J. Characterization of the interaction of two peptides from the N terminus of the nhr domain of HIV-1 gp41 with phospholipid membranes. Biochemistry, 2007, 46, 10572-10584.
75. Korazim, O.; Sackett, K.; Shai, Y. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended. J. Mol. Biol., 2006, 364, 1103-1117.
76. Jaroniec, C. P.; Kaufman, J. D.; Stahl, S. J.; Viard, M.; Blumenthal, R.; Wingfield, P. T.; Bax, A. Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry, 2005, 44, 16167-16180.
77. Rafalski, M.; Lear, J. D.; Degrado, W. F. Phospholipid interactions of synthetic peptides representing the n-terminus of HIV gp41. Biochemistry, 1990, 29, 7917-7922.
78. Sackett, K.; Nethercott, M. J.; Shai, Y.; Weliky, D. P. Hairpin folding of HIV gp41 abrogates lipid mixing function at physiologic ph and inhibits lipid mixing by exposed gp41 constructs. Biochemistry, 2009, 48, 2714-2722.
79. Lev, N.; Fridmann-Sirkis, Y.; Blank, L.; Bitler, A.; Epand, R. F.; Epand, R. M.; Shai, Y. Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: Implication for mode of action. Biochemistry, 2009, 48, 3166-3175.
80. Pascual, R.; Moreno, M. R.; Villalain, J. A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: Implications for the fusion mechanism. J. Virol., 2005, 79, 5142-5152.
81. Charloteaux, B.; Lorin, A.; Crowet, J. M.; Stroobant, V.; Lins, L.; Thomas, A.; Brasseur, R. The N-terminal 12 residue long peptide of HIV gp41 is the minimal peptide sufficient to induce significant T-cell-like membrane destabilization in vitro. J. Mol. Biol., 2006, 359, 597-609.
82. Gomara, M. J.; Lorizate, M.; Huarte, N.; Mingarro, I.; Perez-Paya, E.; Nieva, J. L. Hexapeptides that interfere with HIV-1 fusion pep-tide activity in liposomes block gp41-mediated membrane fusion. FEBS Lett., 2006, 580, 2561-2566.
83. Lorizate, M.; de la Arada, I.; Huarte, N.; Sanchez-Martinez, S.; de la Torre, B. G.; Andreu, D.; Arrondo, J. L. R.; Nieva, J. L. Structural analysis and assembly of the HIV-1 gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence. Biochemistry, 2006, 45, 14337-14346.
84. Sackett, K.; Shai, Y. The HIV-1 gp41 N-terminal heptad repeat plays an essential role in membrane fusion. Biochemistry, 2002, 41, 4678-4685.
85. Shnaper, S.; Sackett, K.; Gallo, S. A.; Blumenthal, R.; Shai, Y. The C- and the N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively. J. Biol. Chem., 2004, 279, 18526-18534.
86. Koenig, B. W.; Ferretti, J. A.; Gawrisch, K. Site-specific deuterium order parameters and membrane-bound behavior of a peptide fragment from the intracellular domain of HIV-1 gp41. Biochemistry, 1999, 38, 6327-34.
87. Gordon, L. M.; Curtain, C. C.; McCloyn, V.; Kirkpatrick, A.; Mobley, P. W.; Waring, A. J. The amino-terminal peptide of HIV-1 gp41 interacts with human serum-albumin. AIDS Res. Hum. Retro-viruses, 1993, 9, 1145-1156.
88. Chang, D. K.; Cheng, S. F.; Trivedi, V. D.; Yang, S. H. The amino-terminal region of the fusion peptide of influenza virus hemagglu-tinin HA2 inserts into sodium dodecyl sulfate micelle with residues 16-18 at the aqueous boundary at acidic pH - oligomerization and the conformational flexibility. J. Biol. Chem., 2000, 275, 19150-19158.
89. Chien, M. P.; Jiang, S. B.; Chang, D. K. The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion. Faseb J., 2008, 22, 1179-1192.
90. Bellamy-McIntyre, A. K.; Bar, S.; Ludlow, L.; Drummer, H. E.; Poumbourios, P. Role for the disulfide-bonded region of human immunodeficiency virus type 1 gp41 in receptor-triggered activa-tion of membrane fusion function. Biochem. Biophys. Res. Comm., 2010, 394, 904-908.
91. Peisajovich, S. G.; Blank, L.; Epand, R. F.; Epand, R. M.; Shai, Y. On the interaction between gp41 and membranes: The immuno-dominant loop stabilizes gp41 helical hairpin conformation. J. Mol. Biol., 2003, 326, 1489-1501.
92. Sackett, K.; Shai, Y. How structure correlates to function for membrane associated HIV-1 gp41 constructs corresponding to the N-terminal half of the ectodomain. J. Mol. Biol., 2003, 333, 47-58.
93. Sun, Z. Y.; Oh, K. J.; Kim, M.; Yu, J.; Brusic, V.; Song, L.; Qiao, Z.; Wang, J. H.; Wagner, G.; Reinherz, E. L. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodo-main region on the viral membrane. Immunity, 2008, 28, 52-63.
94. Gerber, D.; Pritsker, M.; Gunther-Ausborn, S.; Johnson, B.; Blu-menthal, R.; Shai, Y. Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a dl-amino acid-containing fusion peptide -possible recognition of the fusion complex. J. Biol. Chem., 2004, 279, 48224-48230.
95. [95] Buzon, V.; Natrajan, G.; Schibli, D.; Campelo, F.; Kozlov, M. M.; Weissenhorn, W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. Plos Pathog., 2010, 6 (5),e1000880
96. Wang G. NMR of membrane-associated peptides and proteins. Curr. Protein Pep. Sci., 2008, 9, 50-69.
97. Tamm, L. K.; Lai, A. L.; Li, Y. Combined NMR and EPR spec-troscopy to determine structures of viral fusion domains in membranes. Biochim. Biophys. Acta, 2007, 1768, 3052-3060.
98. Biron, Z.; Khare, S.; Quadt, S. R.; Hayek, Y.; Naider, F.; Anglister, J. The 2F5 epitope is helical in the HIV-1 entry inhibitor T-20. Biochemistry, 2005, 44, 13602-13611.
99. Biron, Z.; Khare, S.; Samson, A. O.; Hayek, Y.; Naider, F.; Anglis-ter, J. A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry, 2002, 41, 12687-12696.
100. Schibli, D. J.; Montelaro, R. C.; Vogel, H. J. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry, 2001, 40, 9570-9578.
101. Chou, J. J.; Kaufman, J. D.; Stahl, S. J.; Wingfield, P. T.; Bax, A. Micelle-induced curvature in a water-insoluble HIV-1 ENV peptide revealed by NMR dipolar coupling measurement in stretched poly-acrylamide gel. J. Am. Chem. Soc., 2002, 124, 2450-2451.
102. Balogh, E.; Wu, D.; Zhou, G.; Gochin, M. NMR second site screening for structure determination of ligands bound in the hy-drophobic pocket of HIV-1 gp41. J. Am. Chem. Soc., 2009, 131, 2821-2823.
103. Eckert, D. M.; Malashkevich, V. N.; Hong, L. H.; Carr, P. A.; Kim, P. S. Inhibiting HIV-1 entry: Discovery of d-peptide inhibitors that target the gp41 coiled-coil pocket. Cell, 1999, 99, 103-115.
104. Frey, G.; Rits-Volloch, S.; Zhang, X. Q.; Schooley, R. T.; Chen, B.; Harrison, S. C. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc. Natl. Acad. Sci. USA, 2006, 103, 13938-13943.
105. Stewart, K. D.; Huth, J. R.; Ng, T. I.; McDaniel, K.; Hutchinson, R. N.; Stoll, V. S.; Mendoza, R. R.; Matayoshi, E. D.; Carrick, R.; Mo, H.; Severin, J.; Walter, K.; Richardson, P. L.; Barrett, L. W.; Meadows, R.; Anderson, S.; Kohlbrenner, W.; Maring, C.; Kempf, D. J.; Molla, A.; Olejniczak, E. T. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket. Bioorg. Med. Chem. Lett., 2010, 20, 612-617.
106. Caffrey, M.; Cai, M.; Kaufman, J.; Stahl, S. J.; Wingfield, P. T.; Covell, D. G.; Gronenborn, A. M.; Clore, G. M. Three-dimensional solution structure of the 44 kda ectodomain of SIV gp41. EMBO J., 1998, 17, 4572-4584.
107. Cole, J. L.; Garsky, V. M. Thermodynamics of peptide inhibitor binding to HIV-1 gp41. Biochemistry, 2001, 40, 5633-5641.
108. Sia, S. K.; Carr, P. A.; Cochran, A. G.; Malashkevich, V. N.; Kim, P. S. Short constrained peptides that inhibit HIV-1 entry. Proc. Natl. Acad. Sci. USA, 2002, 99, 14664-14669.
109. Liu, J.; Deng, Y. Q.; Dey, A. K.; Moore, J. P.; Lu, M. Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry, 2009, 48, 2915-2923.
110. Schuy, S.; Schafer, E.; Yoder, N. C.; Hobe, S.; Kumar, K.; Vogel, R.; Janshoff, A. Coiled-coil lipopeptides mimicking the prehairpin intermediate of glycoprotein gp41. Angew. Chem.-Int. Ed., 2009, 48, 751-754.
111. Barz, B.; Wong, T. C.; Kosztin, I. Membrane curvature and surface area per lipid affect the conformation and oligomeric state of HIV-1 fusion peptide: A combined ftir and md simulation study. Bio-chim. Biophys. Acta-Biomem., 2008, 1778, 945-953.
112. Liao, Z. H.; Graham, D. R.; Hildreth, J. E. K. Lipid rafts and HIV pathogenesis: Virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res. Hum. Retroviruses, 2003, 19, 675-687.
113. Harada, S.; Yusa, K.; Monde, K.; Akaike, T.; Maeda, Y. Influence of membrane fluidity on human immunodeficiency virus type 1 entry. Biochem. Biophys. Res. Comm., 2005, 329, 480-486.
114. Quintana, F. J.; Gerber, D.; Kent, S. C.; Cohen, I. R.; Shai, Y. HIV-1 fusion peptide targets the tcr and inhibits antigen-specific T cell activation. J. Clin. Invest., 2005, 115, 2149-2158.
115. Bloch, I.; Quintana, F. J.; Gerber, D.; Cohen, T.; Cohen, I. R.; Shai, Y. T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif. Faseb J., 2007, 21, 393-401.
116. Yang, J.; Gabrys, C. M.; Weliky, D. P. Solid-state nuclear magnetic resonance evidence for an extended beta strand conformation of the membrane-bound HIV-1 fusion peptide. Biochemistry, 2001, 40, 8126-8137.
117. Li, Y.; Tamm, L. K. Structure and plasticity of the human immunodeficiency virus gp41 fusion domain in lipid micelles and bilay-ers. Biophys. J., 2007, 93, 876-885.
118. Tjandra, N.; Omichinski, J. G.; Gronenborn, A. M.; Clore, G. M.; Bax, A. Use of dipolar 1H-15N and 1H-13C couplings in the structure determination of magnetically oriented macromolecules in solution. Nat. Struct. Biol., 1997, 4, 732-738.
119. Jaroniec, C. P.; Kaufman, J. D.; Stahl, S. J.; Viard, M.; Blumenthal, R.; Wingfield, P. T.; Bax, A. Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry, 2005, 44, 16167-16180.
120. Barz, B.; Wong, T. C.; Kosztin, I. Membrane curvature and surface area per lipid affect the conformation and oligomeric state of HIV-1 fusion peptide: A combined ftir and md simulation study. Bio-chim. Biophys. Acta, 2008, 1778(4),945-953
121. Gordon, L. M.; Mobley, P. W.; Pilpa, R.; Sherman, M. A.; Waring, A. J. Conformational mapping of the N-terminal peptide of HIV-1 gp41 in membrane environments using C-13-enhanced fourier transform infrared spectroscopy. Biochim. Biophy. Acta-Biomem., 2002, 1559, 96-120.
122. Li, Y. L.; Tamm, L. K. Structure and plasticity of the human immunodeficiency virus gp41 fusion domain in lipid micelles and bi-layers. Biophy. J., 2007, 93, 876-885.
123. Peisajovich, S. G.; Epand, R. F.; Pritsker, M.; Shai, Y.; Epand, R. M. The polar region consecutive to the HIV fusion peptide participates in membrane fusion. Biochemistry, 2000, 39, 1826-1833.
124. Yang, J.; Parkanzky, P. D.; Khunte, B. A.; Canlas, C. G.; Yang, R.; Gabrys, C. M.; Weliky, D. P. Solid state NMR measurements of conformation and conformational distributions in the membrane-bound HIV-1 fusion peptide. J. Mol. Graph. Model., 2001, 19, 129-135.
125. Qiang, W.; Bodner, M. L.; Weliky, D. P. Solid-state nmr spectros-copy of human immunodeficiency virus fusion peptides associated with host-cell-like membranes: 2D correlation spectra and distance measurements support a fully extended conformation and models for specific antiparallel strand registries. J. Am. Chem. Soc., 2008, 130, 5459-5471.
126. Sackett, K.; Nethercott, M. J.; Epand, R. F.; Epand, R. M.; Kindra, D. R.; Shai, Y.; Weliky, D. P. Comparative analysis of membrane-associated fusion peptide secondary structure and lipid mixing function of HIV gp41 constructs that model the early pre-hairpin intermediate and final hairpin conformations. J. Mol. Biol., 2010, 397, 301-315.
127. Castano, S.; Desbat, B. Structure and orientation study of fusion peptide FP23 of gp41 from HIV-1 alone or inserted into various lipid membrane models (mono-, bi-and multibi-layers) by FR-IR spectroscopies and brewster angle microscopy. Biochim. Biophys. Acta, 2005, 1715, 81-95.
128. Jiang, S.; Lin, K.; Lu, M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol., 1998, 72, 10213-10217.
129. Liu, S. W.; Lu, H.; Niu, J.; Xu, Y. J.; Wu, S.; G.Jiang, S. B. Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem., 2005, 280, 11259-11273.
130. Rabenstein, M.; Shin, Y. K. A peptide from the heptad repeat of human-immunodeficiency-virus gp41 shows both membrane-binding and coiled-coil formation. Biochemistry, 1995, 34, 13390-13397.
131. Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. B.; Matthews, T. J. Peptides corresponding to a predictive alpha-helical domain of human-immunodeficiency-virus type-1 gp41 are potent inhibitors of virus-infection. Proc. Natl. Acad. Sci. USA, 1994, 91, 9770-9774.
132. Chinnadurai, R.; Rajan, D.; Munch, J.; Kirchhoff, F. Human immunodeficiency virus type 1 variants resistant to first-and second-version fusion inhibitors and cytopathic in ex vivo human lym-phoid tissue. J. Virol., 2007, 81, 6563-6572.
133. Eggink, D.; Baldwin, C. E.; Deng, Y. Q.; Langedijk, J. P. M.; Lu, M.; Sanders, R. W.; Berkhout, B. Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol., 2008, 82, 6678-6688.
134. Eggink, D.; Langedijk, J. P. M.; Bonvin, A.; Deng, Y. Q.; Lu, M.; Berkhout, B.Sanders, R.; W. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J. Biol. Chem., 2009, 284, 26941-26950.
135. Melby, T.; Demasi, R.; Cammack, N.; Miralles, G. D.; Greenberg, M. L. Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249. AIDS Res. Hum. Retroviruses, 2007, 23, 1366-1373.
136. Miralles, G. D.; Melby, T.; DeMasi, R.; Zhang, Y.; Spence, R.; Cammack, N.; Matthews, T. J.; Greenberg, M. Baseline and on-treatment gp41 genotype and susceptibility to enfuvirtide (enf) and T-1249 in a 10-day study of T-1249 in patients failing an ENF-containing regimen (T1249-102). Antiviral Ther., 2003, 8, 21.
137. Pan, C. G.; Cai, L. F.; Lu, H.; Qi, Z.Jiang, S. B. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide-sensitive and -resistant HIV type 1 strains. J. Virol., 2009, 83, 7862-7872.
138. Rusconi, S.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. An update in the development of HIV entry inhibitors. Curr. Top. Med. Chem., 2007, 7, 1273-1289.
139. Veiga, A. S.; Santos, N. C.; Loura, L. M. S.; Fedorov, A.; Cas-tanho, M. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J. Am. Chem. Soc., 2004, 126, 14758-14763.
140. Dai, S. J.; Song, H. F.; Dou, G. F.; Qian, X. H.; Zhang, Y. J.; Cai, Y.; Liu, X. W.; Tang, Z. M. Quantification of sifuvirtide in monkey plasma by an on-line solid-phase extraction procedure combined with liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Comm. Mass Spec., 2005, 19, 1273-1282.
141. Liang, Q.; Mao, Y. C.; Yang, S.; Fang, S. S.; Tan, J. X.; Liao, Y. P.; Hu, Z. H. Drug-drug interactions of sifuvirtide with cytochrome p450 1A2, 2A6, 2D6, and 3A4 by using pooled human liver micro-somes and primary human hepatocytes. Drug Metab. Rev., 2006, 38, 93-93.
142. Che, J.; Meng, Q.; Chen, Z.; Hou, Y.; Shan, C.; Cheng, Y. Quantitative analysis of a novel HIV fusion inhibitor (sifuvirtide) in HIV infected human plasma using high-performance liquid chromatog-raphy-electrospray ionization tandem mass spectrometry. J. Phar-maceut. Biomed. Anal., 2010, 51, 927-933.
143. Covens, K.; Megens, S.; Dekeersmaeker, N.; Kabeya, K.; Balza-rini, J.; De Wit, S.; Vandamme, A. M.; Van Laethem, K. The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide. Antiviral Res., 2010, 86, 253-260.
144. Pan, C.; Lu, H.; Qi, Z.; Jiang, S. B. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first-and next-generation HIV-fusion inhibitors. AIDS, 2009, 23, 639-641.
145. Wang, Q. Q.; Xiang, S. S.; Jia, Y. B.; Ou, L.; Chen, F.; Song, H. F.; Liang, Q.; Ju, D. An improved on-line solid phase extraction coupled hplc-ms/ms system for quantification of sifuvirtide in human plasma. J. Chromatog. B-Anal. Technol. Biomed. Life Sci., 2010, 878, 1893-1898.
146. Franquelim, H. G.; Loura, L. M. S.; Santos, N. C.; Castanho, M. Sifuvirtide screens rigid membrane surfaces. Establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides. J. Am. Chem. Soc., 2008, 130, 6215-6223.
147. Franquelim, H. G.; Veiga, A. S.; Weissmuller, G.; Santos, N. C.; Castanho, M. Unravelling the molecular basis of the selectivity of the HIV-1 fusion inhibitor sifuvirtide towards phosphatidylcholine-rich rigid membranes. Biochim. Biophys. Acta-Biomem., 2010, 1798, 1234-1243.
148. Naider, F.; Anglister, J. Peptides in the treatment of AIDS. Curr. Opin. Struct. Biol., 2009, 19, 473-482.
149. Vishwanathan, S. A.; Thomas, A.; Brasseur, R.; Epand, R. F.; Hunter, E.; Epand, R. M. Hydrophobic substitutions in the first residue of the crac segment of the gp41 protein of HIV. Biochemistry, 2008, 47, 124-130.
150. Vishwanathan, S. A.; Thomas, A.; Brasseur, R.; Epand, R. F.; Hunter, E.; Epand, R. M. Large changes in the crac segment of gp41 of HIV do not destroy fusion activity if the segment interacts with cholesterol. Biochemistry, 2008, 47, 11869-11876.
151. Song, L.; Sun, Z. Y.; Coleman, K. E.; Zwick, M. B.; Gach, J. S.; Wang, J. H.; Reinherz, E. L.; Wagner, G.; Kim, M. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc. Natl. Acad. Sci. USA, 2009, 106, 9057-9062.
152. Santos, N. C.; Prieto, M.; Castanho, M. Interaction of the major epitope region of HIV protein gp41 with membrane model systems. A fluorescence spectroscopy study. Biochemistry, 1998, 37, 8674-8682.
153. Gochin, M.; Cai, L. F. The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket. J. Med. Chem., 2009, 52, 4338-4344.
154. Waheed, A. A.; Ablan, S. D.; Sowder, R. C.; Roser, J. D.; Schaff-ner, C. P.; Chertova, E.; Freed, E. O. Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail. J. Virol., 2010, 84, 3121-3126.
155. Waheed, A. A.; Ablan, S. D.; Roser, J. D.; Sowder, R. C.; Schaff-ner, C. P.; Chertova, E.; Freed, E. O. HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease. Proc. Natl. Acad. Sci. USA, 2007, 104, 8467-8471.
156. Waheed, A. A.; Ablan, S. D.; Mankowski, M. K.; Cummins, J. E.; Ptak, R. G.; Schaffner, C. P.; Freed, E. O. Inhibition of HIV-1 replication by amphotericin B methyl ester - selection for resistant variants. J. Biol. Chem., 2006, 281, 28699-28711.
157. Epand, R. F.; Sayer, B. G.; Epand, R. M. The tryptophan-rich region of HIV gp41 and the promotion of cholesterol-rich domains. Biochemistry, 2005, 44, 5525-5531.